Cushing's Syndrome clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
(PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients with Cushing's Disease
open to eligible people ages 6-17
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's disease.
at UCSF
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Sorry, not yet accepting patients
Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease. The investigators propose a pilot,…
at UCLA
Our lead scientists for Cushing's Syndrome research studies include Anthony P. Heaney, MD.
Last updated: